化疗诱导血小板减少的机制及防治措施的研究进展*

doi:10.3969/j.issn.1671-2587.2026.02.023

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (2): 293-299.DOI: 10.3969/j.issn.1671-2587.2026.02.023

化疗诱导血小板减少的机制及防治措施的研究进展^*

周载鑫, 钱宝华, 顾海慧

海军军医大学第一附属医院输血科,上海 200433

收稿日期:2025-07-24 接受日期:2025-08-27 出版日期:2026-04-20 发布日期:2026-04-22
通讯作者: 顾海慧,主要从事临床输血与细胞治疗研究,（E-mail）haihuigu@126.com。
作者简介:周载鑫,主要从事临床输血与血型参比研究,（E-mail）zaixin_zhou@163.com。
基金资助:
^*本课题受国家自然科学基金面上项目（No.81970165）资助

Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia

ZHOU Zaixin, QIAN Baohua, GU Haihui

Department of Transfusion Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433

Received:2025-07-24 Accepted:2025-08-27 Online:2026-04-20 Published:2026-04-22

摘要/Abstract

摘要： 血小板是参与机体止血过程的重要组分,血小板数量下降和/或功能障碍会发生出血。血小板减少是肿瘤患者化学诱导治疗中常见的副作用之一。患者血小板数量严重减少会导致化疗疗程的中断,严重影响患者的治疗效果,若出现3~4级血小板减少,患者将面临严重出血风险,甚至威胁生命安全。异体血小板输注、人重组白介素-11、促血小板生成素等药物已经广泛应用于治疗化疗诱导的血小板减少,但受限于患者本身的基础状况及全球血小板供应困难,这些措施有时候效果并不显著。本文综述了关于化疗诱导血小板减少最新的临床现状,发生机制以及治疗收益,希望能探索更多更新的防治技术和措施。

关键词: 化疗, 血小板减少, 机制, 防治措施

Abstract: Platelet is one of the important components involved in the hemostatic process of the body, and chemotherapy-induced thrombocytopenia is one of the common side effects in the treatment of tumor patients. If PLT count cannot be recovered to 100×109/L, the next chemotherapy course often has to be interrupted, which seriously affects the therapeutic benefit. When the more severe grade 3~4 thrombocytopenia occurs, patients are at risk of severe bleeding, even life-threatening. Transfusion of apheresis platelets, human recombinant interleukin-11, and thrombopoietin have been widely used in the treatment of chemotherapy-induced thrombocytopenia, but the effectiveness of these strategies is not effective due to the patients' own underlying conditions. In this article, we review the latest clinical status, mechanism, and therapeutic benefits of chemotherapy-induced thrombocytopenia in recent years, we hope to explore more updated prevention and treatment techniques and measures.

Key words: Chemotherapy, Thrombocytopenia, Pathogenesis, Therapeutic measures

中图分类号:

R730.53R558+.2

周载鑫, 钱宝华, 顾海慧. 化疗诱导血小板减少的机制及防治措施的研究进展^*[J]. 临床输血与检验, 2026, 28(2): 293-299.

ZHOU Zaixin, QIAN Baohua, GU Haihui. Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 293-299.

参考文献

[1] 中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物相关血小板减少诊疗专家共识(2023版)[J]. 中华医学杂志,2023, 103(33):2579-2590.
[2] 中国输血协会临床输血管理学专业委员会,中华医学会血液学分会,中国药师协会肿瘤药师分会. 靶向药物导致血液系统异常的输血与药物治疗中国专家共识[J]. 临床输血与检验, 2025, 27(1): 1-12.
[3] 中国输血协会人类组织抗原专业委员会,中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识[J]. 临床输血与检验,2022,24(3): 273-278.
[4] 孙少勤. 重组人血小板生成素治疗血液肿瘤化疗所致血小板减少症疗效[J]. 临床输血与检验,2018,20(6):632-635.
[5] Gao A,Zhang L L,Zhong D S.Chemotherapy-induced thrombocytopenia: literature review[J]. Discov Oncol, 2023,14(1):10.
[6] Zwart N R K,Kok D E,Ariyaratne S N H,et al. Folate-associated DNA methylation and chemotherapy-induced toxicities in patients with colorectal cancer[J]. Mol Nutr Food Res,2025,69(14):e70127.
[7] Merza N,Farooqui S K,Dar S H,et al.Folfirinox vs. gemcitabine+nab-paclitaxel as the first-line treatment for pancreatic cancer: a systematic review and meta-analysis[J]. World J Oncol,2023,14(5):325-339.
[8] Zhang Y T,Yang F C,Wang J N,et al.Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review[J]. Front Immunol,2024,15: 1382964.
[9] Benkhadra R,Nayfeh T,Patibandla S K,et al.Systematic review and meta-analysis of cisplatin based neoadjuvant chemotherapy in muscle invasive bladder cancer[J]. Bladder Cancer,2022,8(1):5-17.
[10] Han X,Ge P,Liu S Y,et al.Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies[J]. Front Pharmacol,2023,14:1163805.
[11] Song A B,Al-Samkari H.Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment[J]. Br J Haematol,2025,206(4):1062-1066.
[12] Bakchoul T,Marini I.Drug-associated thrombocytopenia[J]. Hematology,2018,2018(1):576-583.
[13] Al-Samkari H,Kolb-Sielecki J,Safina S Z,et al.Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international,randomised,double-blind, placebo-controlled,phase 3 trial[J]. Lancet Haematol,2022,9(3): e179-e189.
[14] Shaw J L,Nielson C M,Park J K,et al.The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies[J]. Eur J Haematol,2021,106(5):662-672.
[15] Kroll M H,Rojas-Hernandez C,Yee C.Hematologic complications of immune checkpoint inhibitors[J]. Blood,2022,139(25):3594-3604.
[16] Calvo R.Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia[J]. Front Pharmacol,2019,10:454.
[17] Yamashita M,Dellorusso P V,Olson O C, et al.Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer,2020, 20(7):365-382.
[18] Dertinger S D,Avlasevich S L,Torous D K, et al.Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy[J]. Toxicol Sci, 2014,140(2):307-314.
[19] Chen Z,Ren X,Ren R M,et al.The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice[J]. Stem Cell Res Ther,2021,12(1):209.
[20] Al-Samkari H.Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists[J]. Blood Rev,2024,63:101139.
[21] Soff G,Leader A,Al-Samkari H,et al.Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy[J]. J Thromb Haemost,2024,22(1):53-60.
[22] Chai X,Li D G,Cao X L,et al.ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice[J]. Sci Rep,2015,5:10181.
[23] Abdelbaset-Ismail A,Ciechanowicz A K, Bujko K,et al.The Nox2-ROS-Nlrp3 inflammasome signaling stimulates in the hematopoietic stem/progenitor cells lipogenesis to facilitate membrane lipid raft formation[J]. Stem Cell Rev Rep,2023,19(1):92-103.
[24] Akunuru S,Geiger H.Aging,clonality,and rejuvenation of hematopoietic stem cells[J]. Trends Mol Med,2016, 22(8):701-712.
[25] Blank U,Karlsson S.TGF-β signaling in the control of hematopoietic stem cells[J]. Blood,2015,125(23):3542-3550.
[26] Gao X,Carpenter R S,Boulais P E,et al. Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis[J]. Science,2024,385(6709): eadp2065.
[27] Shin J Y,Hu W H,Naramura M,et al.High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias[J]. J Exp Med,2014,211(2):217-231.
[28] Niazi V,Ghafouri-Fard S.Effect of bone marrow niche on hematopoietic stem cells[J]. Histochem Cell Biol, 2024,163(1):19.
[29] Penter L,Liu Y,Wolff J O,et al.Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease[J]. Blood,2023,141(15):1817-1830.
[30] Tang C,Li M H,Chen Y L,et al.Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia[J]. J Exp Clin Cancer Res,2018,37(1):204.
[31] Rafieemehr H,Maleki Behzad M,Azandeh S,et al.Chemo/radiotherapy-induced bone marrow niche alterations[J]. Cancer Invest,2021,39(2):180-194.
[32] Lu R,Lin Q Y,Chen S,et al.Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma[J]. Transl Cancer Res,2020,9(3):1640-1651.
[33] Erdem G U,Dogan M,Demirci N S,et al.Oxaliplatin-induced acute thrombocytopenia[J]. J Cancer Res Ther, 2016,12(2):509-514.
[34] Xue R Y,Li M,Zhang G,et al.GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential[J]. Blood,2024, 144(25):2652-2665.
[35] Gao Z M,Qi N N,Qin X,et al.The addition of tislelizumab
to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single-center study based on propensity score matching[J]. Cancer Med,2023,12(24):22071-22080.
[36] Li J,Wang W Q,Jiang K P,et al.Risk factors of chemotherapy-induced thrombocytopenia after oxaliplatin-containing chemotherapy for gastrointestinal malignancies[J]. J Gastrointest Cancer,2024,55(3): 1144-1153.
[37] 肖函,王利. 肝硬化血小板减少的病理生理发生机制[J]. 实用肝脏病杂志,2019,22(4):462-465.
[38] Soff G,Leader A,Al-Samkari H,et al.Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy[J]. J Thromb Haemost,2024,22(1):53-60.
[39] 唐浩,桂嵘. 血小板输注疗效预测模型在血液肿瘤患者临床用血管理中的应用[J]. 临床输血与检验,2017,19(4): 313-316.
[40] Liu Z R,Wang Y X,Yan J X,et al.Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: A systematic review and meta-analysis[J]. J Eval Clin Pract,2020,26(1):262-271.
[41] Chen M T,Li L,Xia Q,et al.A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter,cross-sectional study[J]. Cancer,2024, 130(S8):1524-1538.
[42] Soff G A,Miao Y M,Bendheim G,et al.Romiplostim treatment of chemotherapy-induced thrombocytopenia[J]. J Clin Oncol,2019,37(31):2892-2898.
[43] Gurumurthy G,Kisiel F,Gurumurthy S,et al.Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis[J]. J Oncol Pharm Pract,2025,31(1):4-11.
[44] Xia X H,Zhou H T,Zhang H,et al.Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors[J]. Res Pract Thromb Haemost,2023,7(7):102231.
[45] Gernsheimer T B,Brown S P,Triulzi D J,et al.Prophylactic
tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial[J]. Blood, 2022,140(11):1254-1262.
[46] Nguyen V Q,Kristensen L,Frederiksen H.Acquired amegakaryocytic thrombocytopaenia after treatment with immune checkpoint inhibitor as part of neoadjuvant treatment in a patient with bilateral breast cancer[J]. BMJ Case Rep,2025,18(3):e263434.
[47] 陈信义,史哲新,侯丽. 肿瘤化疗相关性血小板减少症中医药防治专家共识[J]. 北京中医药,2021,40(5):451-455.
[48] 廖慧妍. 人参防治尼拉帕利所致骨髓抑制的作用和机理研究[D]. 广州:广州中医药大学,2022.
[49] 张院辉,范崇青,龚亚斌. 鹿血晶治疗恶性实体肿瘤化疗所致血小板减少症的随机对照研究[J]. 中医肿瘤学杂志, 2024,6(6):45-50.
[50] 王琴,葛云,徐东,等. 加味花生衣干预治疗吉西他滨联合顺铂方案引起血小板降低的效果及费用调查分析[J]. 现代肿瘤医学,2019,27(1):108-111.
[51] 沈君华. 升板方联合重组人白介素-2治疗化疗后血小板减少疗效观察[J]. 实用中医药杂志,2019,35(10):1241-1242.
[52] 孙静. 归脾汤治疗化疗相关性血小板减少症的临床研究[D]. 成都:成都中医药大学,2023.
[53] 陈娇健,王立森. 黄金昶刺血拔罐治疗化疗相关性血小板减少症经验[J]. 湖北中医杂志,2023,45(7):25-29.

化疗诱导血小板减少的机制及防治措施的研究进展^*

Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	刘艺, 魏婷, 李庆山. 免疫性血小板减少症患者中血小板抗体检测的研究进展^*[J]. 临床输血与检验, 2026, 28(2): 273-279.
[2]	王欣, 李峣, 单卓越, 赵丽艳. CD36抗原缺失与临床输血安全相关研究进展^*[J]. 临床输血与检验, 2026, 28(2): 279-285.
[3]	杜霞, 李茜, 涂源泉, 陈璐, 张智慧, 彭沫溱, 罗臻, 寸伟, 朱祥明. 昆明地区RhD初筛阴性献血者RHD基因多态性及分子机制研究^*[J]. 临床输血与检验, 2026, 28(1): 97-102.
[4]	谢文举, 付子可, 王秋实. 胎儿/新生儿同种免疫性血小板减少症研究进展^*[J]. 临床输血与检验, 2025, 27(6): 882-888.
[5]	马春娅, 张敏, 付丽辉, 朱建玲, 罗圆圆, 关晓珍, 于洋. 哌拉西林钠他唑巴坦钠致药物性血小板减少症的实验室诊断研究[J]. 临床输血与检验, 2025, 27(2): 191-195.
[6]	周心蕙, 左斌, 王文, 何杨. ITP患者外周血脂质谱与促血小板生成药物疗效的相关性分析^*[J]. 临床输血与检验, 2025, 27(1): 115-120.
[7]	夏悦昕, 邵林楠, 李宁, 周世航, 刘志远. 基于PacBio三代测序技术鉴定cisAB亚型及利用分子对接探究其分子机制[J]. 临床输血与检验, 2024, 26(6): 792-796.
[8]	明静, 丁凯阳, 胡茂贵, 王馨辰. 阿伐曲泊帕联合rhTPO在恶性血液病自体造血干细胞移植中的临床疗效分析^*[J]. 临床输血与检验, 2024, 26(6): 812-817.
[9]	杨华月, 娄璨, 雷航, 蔡晓红. 血小板衰老机制研究进展^*[J]. 临床输血与检验, 2024, 26(5): 709-714.
[10]	崔文燕, 刘金华, 付威义. 利用三代测序技术鉴定c.586T>C突变导致的Bel亚型^*[J]. 临床输血与检验, 2024, 26(2): 262-266.
[11]	郑思晴, 王昊. m6A修饰对于肿瘤在传统化疗和新型靶向治疗耐药中的作用研究进展^*[J]. 临床输血与检验, 2023, 25(5): 706-720.
[12]	孙秋爽, 梁卉. 行异基因造血干细胞移植治疗的伴严重血小板减少的儿童MYH9相关疾病1例并文献复习[J]. 临床输血与检验, 2023, 25(4): 544-548.
[13]	唐雀美, 尹明伟, 黄新宇, 洪小珍, 许先国, 陈学军. 1例p血型白血病患儿的用血管理[J]. 临床输血与检验, 2023, 25(3): 411-414.
[14]	葛洪峰, 李淑娥, 楚海亮, 杨世礼, 纪晓娟, 丰江舟, 张司琪, 邢明泉, 梁海. 沙利度胺联合二线方案治疗复发、难治性ITP患者的观察性研究^*[J]. 临床输血与检验, 2023, 25(1): 133-136.
[15]	李晓菲, 张烨, 刘婷婷, 苗天红, 许志远. Ael亚型基因多态性研究[J]. 临床输血与检验, 2022, 24(4): 422-426.